A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC

被引：0

作者：

Hayakawa, Daisuke ^{[1
]}

Takeda, Masayuki ^{[2
,3
]}

Shimokawa, Mototsugu ^{[4
]}

Nakamura, Atsushi ^{[5
]}

Nosaki, Kaname ^{[6
]}

Watanabe, Yasutaka ^{[7
]}

Kato, Terufumi ^{[8
]}

Tanaka, Hiroshi ^{[9
]}

Takahashi, Toshiaki ^{[10
]}

Oki, Masahide ^{[11
]}

Tachihara, Motoko ^{[12
]}

Fujimoto, Daichi ^{[13
]}

Yamaguchi, Kakuhiro ^{[14
]}

Hayashi, Hidetoshi ^{[2
]}

Yamamoto, Shoichiro ^{[15
]}

Iwama, Eiji ^{[16
]}

Azuma, Koichi ^{[17
]}

Yamamoto, Nobuyuki ^{[13
]}

Nakagawa, Kazuhiko ^{[2
]}

机构：

[1] Juntendo Univ, Dept Resp Med, Grad Sch Med, Tokyo, Japan

[2] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[3] Nara Med Univ, Dept Canc Genom & Med Oncol, Kashihara, Nara, Japan

[4] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan

[5] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[7] Saitama Canc Ctr, Div Thorac Oncol, Saitama, Japan

[8] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[9] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[10] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[11] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[12] Kobe Univ, Grad Sch, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[13] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[14] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[15] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephr, Ehime, Japan

[16] Kyushu Univ, Dept Resp Med, Grad Sch Med Sci, Fukuoka, Japan

[17] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan

[18] Japan Lung Canc Alliance, Yokohama, Kanagawa, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O7-2

引用

页码：S1387 / S1387

页数：1

共 50 条

[31] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Luo, Yung-Hung
Liu, Han
Wampfler, Jason A.
Tazelaar, Henry D.
Li, Yalun
Peikert, Tobias
Liu, Dan
Leventakos, Konstantinos
Chen, Yuh-Min
Yang, Yanan
Chiou, Shih-Hwa
Yang, Ping
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2099 - 2114
[32] Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients
Li, Yue
Xu, Yuxia
Wu, Xiaoyan
He, Caiyun
Liu, Qing
Wang, Fang
JOURNAL OF THORACIC DISEASE, 2019, 11 (07) : 3004 - +
[33] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
Li, C.
Liu, H.
Zhang, B.
Zhang, Z.
Su, Y.
Wang, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
[34] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Yung-Hung Luo
Han Liu
Jason A. Wampfler
Henry D. Tazelaar
Yalun Li
Tobias Peikert
Dan Liu
Konstantinos Leventakos
Yuh-Min Chen
Yanan Yang
Shih-Hwa Chiou
Ping Yang
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
[35] EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
Holzer, Sophia
Hochmair, Maximilian
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Britt-Madelaine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto Chris
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) : 769 - 770
[36] Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
Cheema, P.
Passaro, A.
Martin, C.
Tiseo, M.
Park, K.
Chang, G.
Hu, Y.
Cho, B. C.
Miranda, M.
Fernandes, A.
Freitas, H.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S854 - S854
[37] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
Mohorcic, K.
Janzic, A.
Janzic, U.
Rot, M.
Kern, I.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
[38] Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study
Schmid, S.
Klingbiel, D.
Aeppli, S.
Britschgi, C.
Gautschi, O.
Pless, M.
Rothschild, S. I.
De Nicola, L. Wannesson
Janthur, D.
Foerbs, D.
Demmer, I.
Jochum, W.
Fruh, M.
ANNALS OF ONCOLOGY, 2018, 29
[39] Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment
Furuta, Hiromi
Uemura, Takehiro
Yoshida, Tatsuya
Kobara, Makiko
Yamaguchi, Teppei
Watanabe, Naohiro
Shimizu, Junichi
Horio, Yoshitsugu
Kuroda, Hiroaki
Sakao, Yukinori
Yatabe, Yasushi
Hida, Toyoaki
ANTICANCER RESEARCH, 2018, 38 (09) : 5231 - 5237
[40] Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)
Xing, L.
Pan, Y.
Shi, Y.
Shu, Y.
Feng, J.
Li, W.
Cao, L.
Wang, L.
Gu, W.
Song, Y.
Yu, J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592

← 1 2 3 4 5 →